RECENT

M&A
in
PHARMA

1
 REASONS FOR M& A

A B C

NETW- R&D COST

ORK INVESTMENT
2
 Mergers and
acquisitions to drive
growth in
pharma sector

323 transactions (2016: 345),

USD 120bn (2016: USD 95bn).
2014 and 2015, there were 440 to 490- USD 225bn.

MM.DD.20XX
3
ADD A FOOTER
 The bigger picture

 Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas

porttitor congue massa.
 Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada
libero, sit amet commodo magna eros quis urna.
 Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.

Other developed market and emerging market… 4

Largest Transaction !!!
 USD 30bn
 Swiss-based specialist in Pulmonary
Arterial Hypertension (PAH), and
Europe’s largest Bio- tech company.
 J&J agreed to pay CHF 280 per share.
 The valuation is perceived as very high,
corresponding to 12 times revenues and
30 times EBIT.
5
 USD 11.9 BN

axicabtagene ciloleucel (Axi-cel)

Just before therapy against a form of B-cell cancer was approved

Gilead
HIV/AIDS therapies- 1990

“Pipeline Deals”
Hepatitis C treatments Sovaldi and Harvoni, (2011- Pharmasset)

Kite’s technology
chimeric antigen receptor T-cell (CART) therapy
Big bets on cancer

6
After a relatively quiet 12 months for
mergers and acquisitions in 2017,
this year is expected to produce a HOT COMPANIES!!!
bumper crop of deals between big
 Juno and Bluebird CAR-T
pharma and biotech. drugs- $8.68bn
 Spark Therapeutics- gene
therapy field-
Luxturna approved by the
WATCH OUT FOR FDA DEC 2017, $850,000
 Clovis, the (Arizona)- price for the one-off treatment.
ovarian cancer space with
corporation tax Rubrca. -$3.32 billion  BioMarin- gene therapy for
 Puma Biotech- breast cancer haemophilia A
drug neratinib- $3.59 bn
reduce corporation tax
from 35% to 21%  Sage Therapeutics- SAGE-
217 showed clear benefits in
income earned overseas – its phase 3 trial, while
these will be taxed brexanolone- Depression-
between 8 and 15.5% $6.83 billion
instead of the current 35%
7
 M & A- 2018

Sanofi agreed to buy U.S. hemophilia expert Bioverativ for $11.6 billion
Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it
does not already own.

8
THANK
YOU!
: